Topical bevacizumab for neovascular glaucoma: a pilot study.

@article{Waisbourd2014TopicalBF,
  title={Topical bevacizumab for neovascular glaucoma: a pilot study.},
  author={Michael Waisbourd and Gabi Shemesh and Shimon Kurtz and Rony Rachmiel and Elad Moisseiev and Shiri Zayit-Soudri and Anat Loewenstein and Irina S. Barequet},
  journal={Pharmacology},
  year={2014},
  volume={93 3-4},
  pages={108-12}
}
BACKGROUND/AIMS Bevacizumab (Avastin), an anti-vascular endothelial growth factor drug, has been successfully used in recent years to treat ocular pathologies, mostly by intravitreal administration. The aim of this study was to investigate the safety and efficacy of topically applied bevacizumab for the treatment of neovascular glaucoma (NVG). METHODS Patients with NVG were treated with topical bevacizumab (25 mg/ml) 4 times daily during 2 weeks. The following parameters were evaluated at… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 26 references

Anti-VEGF therapy for glaucoma.

Current opinion in ophthalmology • 2010

Similar Papers

Loading similar papers…